Molecular structure of Vandetanib, CAS Number: 443913-73-3
Vandetanib (CAS 443913-73-3)
Alternate Names:
N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine
Application:
Vandetanib is an antagonist of VEGFR (Flk and Flk) and EGFR families.
CAS Number:
443913-73-3
Purity:
≥98%
Molecular Weight:
475.35
Molecular Formula:
C22H24BrFN4O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Vandetanib is a chemical compound that is extensively studied in various research applications for its ability to inhibit certain protein kinases. It has been the subject of numerous studies focusing on its interaction with epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR), which are important in the regulation of cell growth and angiogenesis. Vandetanib is also involved in the investigation of signal transduction pathways and their role in cellular processes, which contributes to the understanding of how cells communicate and respond to their environment. In materials science, research on Vandetanib may extend to its physical properties and stability under different laboratory conditions. Additionally, Vandetanib′s role in modulating kinase activity makes it a point of interest in the study of molecular mechanisms that govern cellular functions and responses in a controlled research setting.
Vandetanib (CAS 443913-73-3) References
- Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. | Takeda, H., et al. 2013. Exp Cell Res. 319: 417-23. PMID: 23274758
- Vandetanib-induced phototoxicity in human keratinocytes NCTC-2544. | Salvador, A., et al. 2014. Toxicol In Vitro. 28: 803-11. PMID: 24681205
- Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers. | Hatem, R., et al. 2016. Int J Cancer. 138: 2510-21. PMID: 26686064
- Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells. | Starenki, D., et al. 2017. Cancer Biol Ther. 18: 473-483. PMID: 28475408
- Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion. | Li, C., et al. 2018. Oncol Rep. 39: 1757-1764. PMID: 29436676
- Long-term cardiovascular effects of vandetanib and pazopanib in normotensive rats. | Cooper, SL., et al. 2019. Pharmacol Res Perspect. 7: e00477. PMID: 31164986
- Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver Cancer. | Duran, R., et al. 2019. Radiology. 293: 695-703. PMID: 31617791
- Effects of adenosine triphosphate on vandetanib induced skin damage in rats. | Akagunduz, B., et al. 2020. Cutan Ocul Toxicol. 39: 323-327. PMID: 32722951
- Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma. | Kitamura, S., et al. 2020. Biochem Biophys Res Commun. 531: 396-401. PMID: 32800552
- Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2. | Tanihara, Y., et al. 2021. Eur J Pharm Sci. 158: 105666. PMID: 33296710
- Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model. | Carra, S., et al. 2021. Int J Mol Sci. 22: PMID: 33809722
- Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma. | Carvalho, DM., et al. 2022. Cancer Discov. 12: 416-431. PMID: 34551970
- Novel vandetanib derivative inhibited proliferation and promoted apoptosis of cancer cells under normoxia and hypoxia. | Yin, L., et al. 2022. Eur J Pharmacol. 922: 174907. PMID: 35331723
- Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4. | Ma, W., et al. 2022. Mol Oncol. 16: 2747-2765. PMID: 35689424
Inhibitor of:
3100002L24Rik, 3Gn-T6, 6130401L20Rik, 6330545A04Rik, 7530416G11Rik, AI182371, AI316807, ALG11, AMBP, AML-2, AMPKα2, Angptl1, APPL1, ASPH, BAALC, BB114814, BC021395, BC034069, BC049349, BC049730, BC055004, BSPH1, BXDC5, C11orf60, C11orf94, C5orf34_4833420G17Rik, CASKIN2, Cbl-3, CCDC60_Ccdc60, CCT B, CD93, CEACAM19, CEACAM20, CLLD6, CLU1, CMS, CNK1, Consortin, Cxx1b, CYBASC3, CYHR1, DC-TM4F2, DCIR2, DDR2, Dist1, DLEC1, DNAJC25-GNG10, Dok-4, Dok-5, Dok-7, E-Ras, EFR3A, EG-VEGF, EGF, EGFL6, EGFL7, EGFR, Eph A8, Epiregulin, ETL, EVI2B, F8A3, FAM184A, FAM189B, FAM75C2, FAXC, Fes, FHL-5, Flk-1, Flt-1, Flt-4, FLTR1, Gm447, Gm960, H2-22, H2-Kk, HCCA2, HPS-4, HSTF4, IGSF10, ILEI, IRR, Isthmin, KHS, KIAA1522, KKIAMRE, KNP-I, LDOC1, LERK-3, LOC284009, LOC388339, LOC390031, LOC440087, LOC641696, LOC647238, LPRP, Lsk_Ctk, Mare, MAST1, Mig-6, MPND, NET-2, neuropilin, Niban, NK10, NOK, Olfr1354, Olfr157, Olfr208, Olfr393, Olfr541, Olr1002, Olr1060, Olr1065, Olr1220, Olr1231, Olr1234, Olr1259, Olr1295, Olr1307, Olr1320, Olr1385, Olr1397, Olr1528, Olr1560, Olr1561, Olr1576, Olr1622, Olr164, Olr1641, Olr175, Olr185, Olr223, Olr272, Olr354, Olr361, Olr516, Olr517, Olr554, Olr569, Olr598, Olr697, Olr714, Olr72, Olr727, Olr742, Olr749, Olr773, Olr83, Olr836, Olr951, Olr956, Olr982, OTTMUSG00000004968, OTTMUSG00000019138, PDGFR-beta, PEAR1, PIG-F, PKR1, PRAMEF21, Prolifera, Proliferin-1, PSCA, PTOV1, PTPRQ, Renal Cell Carcinoma, Ret, RETL2, RNF213, robo4, Rse, RSHL1, RSP3, RUSC2, Sad-1, SCGBL, SEF14, Sfta2, SGEF, SGS2, Shc4, Slap, Sm D1, Spot-2, Srb4, ST, SUP, TCP-c, TEM7, TEM7R, Tie-2, TM, TMEM114, Trav13d-4, Trav2, Trav3n-2, TREM-2b, TSHR, Txk, Vasohibin-2, vasostatin II, VEGF-D, VG5Q, VHR, Vmn1r118, Vmn1r57, Vmn2r27, Vmn2r46, Vmn2r5, Vmn2r52, Vmn2r60, VSIG10, VSIG10L, WDR31, XAGE-1, and ZNF26.Activator of:
FLJ42117, PIWIL2, PlGF, Tie-1, and Vasohibin-1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Vandetanib, 5 mg | sc-220364 | 5 mg | $167.00 | |||
Vandetanib, 50 mg | sc-220364A | 50 mg | $1353.00 |